Soleno Therapeutics (SLNO) Non-Current Deferred Tax Liability (2017 - 2023)
Soleno Therapeutics (SLNO) reported Non-Current Deferred Tax Liability of $1.9 million for Q4 2023, up 20.19% on a QoQ basis from $1.6 million in Q4 2018.
Soleno Therapeutics (SLNO) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $1.9 million in Q4 2023.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.9 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.9 million (changed N/A YoY) and the FY2023 annual result came in at $1.9 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability rose to $1.9 million in Q4 2023 per SLNO's latest filing, from $1.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.9 million in Q4 2023 and bottomed at $1.9 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2023 | 1.92 Mn |
| Dec 31, 2018 | 1.60 Mn |
| Dec 31, 2018 | 1.60 Mn |
| Dec 31, 2017 | 1.60 Mn |
| Dec 31, 2017 | 1.60 Mn |